Literature DB >> 15152615

[Early treatment of a Bence-Jones-kappa-light-chain-paraproteinemia].

W A Bethge1, H Einsele.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15152615     DOI： 10.1007/s00108-004-1148-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  8 in total

1.  Total therapy with tandem transplants for newly diagnosed multiple myeloma.

Authors:  B Barlogie; S Jagannath; K R Desikan; S Mattox; D Vesole; D Siegel; G Tricot; N Munshi; A Fassas; S Singhal; J Mehta; E Anaissie; D Dhodapkar; S Naucke; J Cromer; J Sawyer; J Epstein; D Spoon; D Ayers; B Cheson; J Crowley
Journal:  Blood       Date:  1999-01-01       Impact factor: 22.113

2.  Prognostic features of asymptomatic multiple myeloma.

Authors:  D M Weber; M A Dimopoulos; L A Moulopoulos; K B Delasalle; T Smith; R Alexanian
Journal:  Br J Haematol       Date:  1997-06       Impact factor: 6.998

3.  A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  N Engl J Med       Date:  2002-02-21       Impact factor: 91.245

4.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Authors:  J Anthony Child; Gareth J Morgan; Faith E Davies; Roger G Owen; Susan E Bell; Kim Hawkins; Julia Brown; Mark T Drayson; Peter J Selby
Journal:  N Engl J Med       Date:  2003-05-08       Impact factor: 91.245

5.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

Authors:  M Attal; J L Harousseau; A M Stoppa; J J Sotto; J G Fuzibet; J F Rossi; P Casassus; H Maisonneuve; T Facon; N Ifrah; C Payen; R Bataille
Journal:  N Engl J Med       Date:  1996-07-11       Impact factor: 91.245

6.  Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.

Authors:  David G Maloney; Arthur J Molina; Firoozeh Sahebi; Keith E Stockerl-Goldstein; Brenda M Sandmaier; William Bensinger; Barry Storer; Ute Hegenbart; George Somlo; Thomas Chauncey; Benedetto Bruno; Frederick R Appelbaum; Karl G Blume; Stephen J Forman; Peter McSweeney; Rainer Storb
Journal:  Blood       Date:  2003-07-10       Impact factor: 22.113

7.  Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance.

Authors:  J Blade; A Lopez-Guillermo; C Rozman; F Cervantes; C Salgado; J L Aguilar; J L Vives-Corrons; E Montserrat
Journal:  Br J Haematol       Date:  1992-07       Impact factor: 6.998

8.  Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden.

Authors:  M Hjorth; L Hellquist; E Holmberg; B Magnusson; S Rödjer; J Westin
Journal:  Eur J Haematol       Date:  1993-02       Impact factor: 2.997
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.